Re: Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

[Lynch HT], [Ghadirian P], et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-9. (2) de Bock GH, Tollenaar RA, Papelard H, Cornelisse CJ, Devilee P, van de Vijver MJ. Clinical and pathological features of BRCA1 associated ca...

Full description

Saved in:
Bibliographic Details
Published inJNCI : Journal of the National Cancer Institute Vol. 95; no. 13; p. 1012
Main Authors Rookus, Matti A., Brohet, Richard, van Leeuwen, Flora E.
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 02.07.2003
Oxford Publishing Limited (England)
Subjects
Birth control
Breast cancer
Breast Neoplasms - chemically induced
Breast Neoplasms - genetics
Case-Control Studies
Confounding Factors (Epidemiology)
Contraceptives, Oral, Hormonal - adverse effects
Female
Genes, BRCA1
Genes, BRCA2
Genetic research
Health risk assessment
Heterozygote
Humans
Mutation
Observer Variation
Odds Ratio
Patient Selection
Research Design
Risk Factors
Survival Analysis
Online AccessGet full text

Cover

More Information
Summary:[Lynch HT], [Ghadirian P], et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-9. (2) de Bock GH, Tollenaar RA, Papelard H, Cornelisse CJ, Devilee P, van de Vijver MJ. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. Br J Cancer 2001;85:1347-50. (3) Central Department of Statistics of The Netherlands. Enkele vormen van geboortenregeling.
Bibliography:istex:323265A3F947FE1D39DC64E90B53AEB68FE2D94D
Correspondence to: M. A. Rookus, Ph.D., Department of Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands (e-mail: m.rookus@nki.nl).
local:0951012
ark:/67375/HXZ-6MMVPZ1S-F
PII:1460-2105
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/95.13.1012